Combination immunotherapy for advanced esophageal cancer after prior treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have esophageal squamous cell carcinoma that has spread or cannot be removed by surgery, and you have already tried first-line immunotherapy plus chemotherapy without success.
- You are able to swallow pills and have good overall health (ECOG score 0-1).
- Your blood counts, liver and kidney function are within certain limits (your doctor can check).
- You have not been treated with adebrelimab, apatinib, or tegafur before, and you do not have active bleeding, fistula, or uncontrolled heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining a new immunotherapy drug (adebrelimab) with standard chemotherapy can help shrink borderline resectable esophageal squamous cell carcinoma before surgery. The goal is to make tumors easier to remove and improve survival.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy and radiation improves outcomes for patients with esophageal squamous cell carcinoma before surgery. The goal is to shrink the tumor and improve survival.
This trial tests a combination of immunotherapy (adebrelimab) plus standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if adding the immunotherapy before and during chemoradiation helps control the cancer better.
This trial tests a new drug called adebrelimab (an immunotherapy) combined with chemotherapy, endoscopy, and radiation for people with early-stage esophageal cancer that cannot be removed with surgery. The goal is to see if this combination can shrink or control the cancer without needing surgery.
This trial tests a personalized treatment approach for advanced esophageal cancer that has stopped responding to immunotherapy. It aims to find better options for people whose cancer has progressed after standard treatments.
This trial is testing a combination of three medications—chidamide, camrelizumab, and apatinib—for people with advanced esophageal cancer. The goal is to see if this combination can help control the cancer and potentially improve outcomes for patients who have received prior treatments.
Hear when a new Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.